Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.548 GBX | -6.18% | -4.15% | -32.70% |
Apr. 25 | EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout | AN |
Apr. 25 | Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 12.98M |
---|---|---|---|---|---|
Net income 2021 | -5M | Net income 2022 | -3M | EV / Sales 2021 | - |
Net cash position 2021 | 6.83M | Net Debt 2022 | 890K | EV / Sales 2022 | - |
P/E ratio 2021 |
-2.85
x | P/E ratio 2022 |
-3.26
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.27% |
1 day | -6.18% | ||
1 week | -4.15% | ||
Current month | -12.05% | ||
1 month | -12.05% | ||
3 months | -41.58% | ||
6 months | -26.29% | ||
Current year | -32.70% |
Managers | Title | Age | Since |
---|---|---|---|
Alexis Sandler
FOU | Founder | - | 11-12-31 |
Founder | 59 | 11-12-31 | |
Elina Shrestha
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Redmond
BRD | Director/Board Member | 76 | 17-10-03 |
Marc Feldmann
CHM | Chairman | 79 | 18-04-08 |
Founder | 59 | 11-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 1.548 | -6.18% | 10,976,230 |
24-04-26 | 1.65 | +4.10% | 1,887,787 |
24-04-25 | 1.585 | -1.43% | 5,559,012 |
24-04-24 | 1.608 | -1.29% | 5,063,450 |
24-04-23 | 1.629 | +0.87% | 4,149,071 |
Delayed Quote London S.E., April 29, 2024 at 11:35 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-32.70% | 27.58M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- HEMO Stock